Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction

被引：0
|
作者：
D'Haens, Geert [1 ]
Navabi, Seyedehsan [2 ]
Chan-Diehl, Faye [3 ]
Moses, Richard E. [3 ]
Walter, James [4 ]
Gibble, Theresa Hunter [3 ]
Laharie, David [5 ]
Gisbert, Javier P. [6 ]
Vermeire, Severine [7 ]
Kobayashi, Taku [8 ]
Regueiro, Miguel [9 ]
Johns, Jordan [3 ]
Charabaty, Aline [10 ]
机构：
[1] Univ Amsterdam, Med Ctr, Amsterdam, Noord Holland, Netherlands
[2] United Med Doctors, Long Beach, CA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Einstein Healthcare Network, Philadelphia, PA USA
[5] Ctr Hosp Univ Bordeaux, Bordeaux, France
[6] Hosp Univ La Princesa, Madrid, Spain
[7] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[8] Kitasato Univ, Ctr Adv IBD Res & Treatment, Kitasato Inst Hosp, Tokyo, Japan
[9] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[10] Johns Hopkins Sch Med, Potomac, MD USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1139
引用
收藏
页码：S871 / S872
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
    Vermeire, S.
    Danese, S.
    Zhou, W.
    Pangan, A.
    Greenbloom, S.
    D'Haens, G.
    Panes, J.
    Juillerat, P.
    Lindsay, J. O.
    Loftus, E. V., Jr.
    Sandborn, W. J.
    Reinisch, W.
    Gonzalez, Y. Sanchez
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M. A.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
  • [42] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
    Sands, Bruce E.
    Rubin, David T.
    Lichtenstein, Gary
    Shipitofsky, Nicole
    Huang, Kuan-Hsiang
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    DuVall, Aaron
    Cao, Qian
    Allegretti, Jessica R.
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S526 - S527
  • [43] Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, G. Y.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 785 - 786
  • [44] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study
    Begun, J.
    Dubinsky, M. C.
    Irving, P. M.
    Li, X.
    Howaldt, S.
    Pokrotnieks, J.
    Krueger, K.
    Laskowski, J.
    Lissoos, T.
    Milata, J.
    Morris, N.
    Arora, V.
    Milch, C.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133
  • [45] Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy
    Sands, Bruce
    D'Haens, Geert
    Sandborn, William J.
    Hibi, Toshifumi
    Su, Chinyu
    Niezychowski, Wojciech
    Ghosh, Subrata
    Zhang, Haiying
    Yu, Dahong
    Woodworth, Deborah
    Healey, Paul
    Marren, Amy
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S261 - S261
  • [46] Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
    Reinisch, Walter
    Loftus Jr, Edward, V
    Schreiber, Stefan
    Rubin, David T.
    Louis, Edouard
    Hecht, Patrick M.
    Barrachina, Elena Marced
    Kalabic, Jasmina
    Vladea, Ramona
    Sharma, Dolly
    Duan, Weijiang Rachel
    Zhang, Yafei
    Panaccione, Remo
    JOURNAL OF CROHNS & COLITIS, 2025, 19 (04):
  • [47] Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
    Kobayashi, Taku
    Ito, Hiroaki
    Ashida, Toshifumi
    Yokoyama, Tadashi
    Nagahori, Masakazu
    Inaba, Tomoki
    Shikamura, Mitsuhiro
    Yamaguchi, Takayoshi
    Hori, Tetsuharu
    Pinton, Philippe
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2021, 19 (04) : 448 - +
  • [48] Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis
    Dubinsky, Marla C.
    Betts, Keith A.
    LaPensee, Kenneth
    Eren, Devrim
    Kim-Romo, Dawn
    Yin, Lei
    Tang, Wenxi
    Gupte-Singh, Komal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S314 - S314
  • [49] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [50] THE EFFICACY AND SAFETY OF ADALIMUMAB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PREDICTORS OF RESPONSE IN KOREA.
    Shin, Seung Yong
    Park, Soo Jung
    Kim, Young
    Im, Jong Pil
    Kim, Hyo-Jong
    Lee, Kang-Moon
    Kim, Ji Won
    Jung, Sung-Ae
    Lee, Jun
    Kang, Sang-Bum
    Shin, Sung Jae
    Kim, Eun Sun
    Kim, You Sun
    Kim, Tae Oh
    Kim, Hyun Soo
    Park, Dongil
    Kim, Hyungkil
    Kim, Eun Soo
    Kim, Dohyun
    Teng, Dennis
    Kim, Jong-Hwa
    Kim, Wonyong
    Choi, Chang Hwan
    GASTROENTEROLOGY, 2020, 158 (06) : S1206 - S1206
12345